Foal Immunodeficiency Syndrome
Learn what the condition is, how it may be detected early, how it is treated or managed, and which breeds or species are linked to it.
Condition snapshot
A concise guide to the condition’s pattern, detection, management and urgency.
Breeding advice appliesUse the screening guidance and veterinary or genetics advice before breeding an affected or at-risk animal.
This snapshot is a general guide, not a diagnosis or treatment plan. New, severe or worsening signs require veterinary assessment.
About the condition
Foal immunodeficiency syndrome, or FIS, is a fatal recessive disorder recognised in Fell and Dales ponies. A SLC5A3 variant disrupts a sodium–myo-inositol transporter and causes progressive failure of B lymphocytes. Affected foals can absorb maternal antibody normally, so they may appear healthy early in life before their own antibody production is required.
From several weeks to a few months of age, foals develop repeated respiratory or gastrointestinal infection, poor growth, lethargy and persistent diarrhoea. Pneumonia and opportunistic infections respond poorly or recur after antimicrobial treatment. Progressive anaemia is a notable feature and can become severe. Unlike SCID, in which both B- and T-cell arms are profoundly defective in Arabian foals, FIS has its own breed distribution, mutation and immunological pattern.
The syndrome is not directly contagious, although secondary infectious agents may spread. Failure of passive transfer, parasitism, nutritional disease and ordinary sepsis can resemble parts of the presentation and may be treatable. Affected FIS foals, however, cannot establish normal humoral immunity and inevitably deteriorate.
Carriers remain healthy. A mating between two carriers has a 25% affected risk for each foal, while historical loss of young foals can conceal the disorder in a family. There is no curative immune replacement available in horses; affected foals die or require humane euthanasia. Validated DNA screening before breeding is therefore central to control and permits carriers with desirable qualities to be paired safely with genetically clear ponies.
Progressive anaemia distinguishes many FIS cases from simple passive-transfer failure and reflects the broader consequence of the SLC5A3 defect. The restriction to Fell and Dales pony populations helps direct testing, but crossbred ancestry can be overlooked. Temporary improvement after antibiotics treats an opportunist, not the continuing immune decline.
Screening & Early Detection
FIS is suspected in a Fell or Dales pony foal with recurrent infection, chronic diarrhoea, failure to thrive and progressive anaemia. Serial complete blood counts track anaemia and lymphocyte changes. Serum immunoglobulins, lymphocyte phenotyping and response to infection help characterise immune failure, while cultures, thoracic imaging, faecal testing and ultrasound identify secondary disease.
Passive-transfer testing is interpreted by age: adequate early IgG does not exclude FIS because maternal antibody can initially mask the foal's inability to produce its own. A validated SLC5A3 DNA test confirms clear, carrier or affected genotype from blood or rooted hair. Parentage and breed identity are checked if results are unexpected.
Breeding Fell and Dales ponies are tested before mating, including healthy adults from families without a known case. Relatives are assigned only probabilities until directly tested. A negative FIS result excludes the recognised variant but does not rule out acquired immunodeficiency, SCID or other causes of recurrent infection. Necropsy and stored DNA are valuable after unexplained early foal death.
Treatment & Management
Antimicrobials selected from culture, fluids, plasma, oxygen, nutrition and diarrhoea care may control individual infections temporarily. Blood transfusion may be required for life-threatening anaemia. None of these measures restores durable B-cell function, and repeated relapses are expected as maternally derived protection disappears.
Once homozygous FIS is confirmed in a clinically affected foal, humane euthanasia is recommended before severe anaemia, pneumonia, diarrhoea and invasive procedures cause further suffering. During investigation the foal receives clean isolation and barrier nursing, both to reduce its exposure and to contain secondary pathogens. The mare needs no treatment for the foal's genetic defect.
Prevention is achieved by DNA-guided mating. Clear-to-clear and carrier-to-clear pairings cannot produce an affected foal from the known variant; carrier offspring from the latter must be identified before breeding. Two carriers are never paired. Healthy carriers require no medication and need not all be removed, which would unnecessarily narrow small pony populations. Test reports are linked to permanent identification and disclosed with breeding or sale. Following an affected foal, both parents and close breeding relatives are tested directly, and future plans use verified genotype rather than assuming that prior healthy offspring made the cross safe.
